Genesystem Co. Ltd.
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterina… Read more
Genesystem Co. Ltd. (363250) - Total Liabilities
Latest total liabilities as of September 2025: ₩8.04 Billion KRW
Based on the latest financial reports, Genesystem Co. Ltd. (363250) has total liabilities worth ₩8.04 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genesystem Co. Ltd. - Total Liabilities Trend (2018–2024)
This chart illustrates how Genesystem Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genesystem Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Genesystem Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
InkTec Co. Ltd
KQ:049550
|
Korea | ₩85.01 Billion |
|
Elmer Bancorp Inc
PINK:ELMA
|
USA | $367.21 Million |
|
PT Jakarta International Hotels & Development Tbk
MU:JAK1
|
Germany | €1.87 Trillion |
|
Precision Optics Corporation, Inc. Common stock
NASDAQ:POCI
|
USA | $13.57 Million |
|
Chen Hsong Holdings Limited
PINK:CHHGF
|
USA | $1.20 Billion |
|
Wooyang Co. Ltd
KQ:103840
|
Korea | ₩105.14 Billion |
|
Xander International
TWO:6118
|
Taiwan | NT$2.53 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Genesystem Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genesystem Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genesystem Co. Ltd. (2018–2024)
The table below shows the annual total liabilities of Genesystem Co. Ltd. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩10.63 Billion | -7.34% |
| 2023-12-31 | ₩11.47 Billion | +88.91% |
| 2022-12-31 | ₩6.07 Billion | -7.60% |
| 2021-12-31 | ₩6.57 Billion | -0.47% |
| 2020-12-31 | ₩6.60 Billion | -55.18% |
| 2019-12-31 | ₩14.73 Billion | +13.30% |
| 2018-12-31 | ₩13.00 Billion | -- |